etiocholanolone has been researched along with Heart Failure in 32 studies
Etiocholanolone: The 5-beta-reduced isomer of ANDROSTERONE. Etiocholanolone is a major metabolite of TESTOSTERONE and ANDROSTENEDIONE in many mammalian species including humans. It is excreted in the URINE.
3alpha-hydroxy-5beta-androstan-17-one : An androstanoid that is 5beta-androstane substituted by an alpha-hydroxy group at position 3 and an oxo group at position 17. It is a metabolite of testosterone in mammals.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effects of istaroxime in patients hospitalized for acute heart failure (AHF) related Society for Cardiovascular Angiography and Interventions (SCAI) stage B pre-cardiogenic shock (CS)." | 9.51 | Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC). ( Chioncel, O; Cotter, G; Davison, B; Filippatos, G; Mebazaa, A; Metra, M; Novosadova, M; Ponikowski, P; Simmons, P; Simonson, S; Soffer, J, 2022) |
| "Istaroxime decreases PCWP, increases SBP, and decreases diastolic stiffness in patients with acute heart failure syndrome." | 9.14 | Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in P ( Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Grzybowski, J; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Shah, SJ; Valentini, G, 2009) |
| "We examined the hemodynamic, echocardiographic, and neurohormonal effects of intravenous istaroxime in patients hospitalized with heart failure (HF)." | 9.13 | Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. ( Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Valentini, G, 2008) |
| "Sigma-Tau Ind Farm Riunite SpA and Debiopharm SA are developing istaroxime, the lead in a series of Na(+)/K(+)-ATPase inhibitors, for the potential treatment of cardiac failure." | 8.84 | Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure. ( Wehrens, XH, 2007) |
| "Istaroxime is a new luso-inotropic compound selected for the treatment of acute heart failure syndromes, which reduces sodium-potassium adenosine triphosphatase (ATPase) activity and stimulates the sarcoplasmic calcium ATPase isoform 2 reuptake function." | 7.74 | Istaroxime: a new luso-inotropic agent for heart failure. ( Borsini, F; Carminati, P; Gagnol, JP; Lo Giudice, P; Loi, FM; Mattera, GG; Vanoli, E, 2007) |
| "Istaroxime (PST2744) is a luso-inotrope that stimulates the sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a without chronotropic effects." | 6.73 | A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. ( Amato, A; Carminati, P; Cowart, D; Ghali, JK; Gheorghiade, M; Haynos, W; Rayburn, BK; Smith, WB; Torre-Amione, G; Valentini, G; Zhang, D, 2007) |
| "Istaroxime is a unique agent with both inotropic and lusitropic properties which is currently being studied for the treatment of AHFS." | 6.45 | Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? ( Blair, JE; Filippatos, GS; Gheorghiade, M; Harinstein, ME; Khan, H; Metra, M; Porchet, H; Sabbah, HN; Valentini, G; Vogel, M, 2009) |
| "Istaroxime was shown, in a small study, to increase systolic blood pressure (SBP) in patients with pre-cardiogenic shock (CS) due to acute heart failure (AHF)." | 5.69 | Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock. ( Adamo, M; Chioncel, O; Cotter, G; Davison, B; Filippatos, G; Mebazaa, A; Metra, M; Novosadova, M; Pagnesi, M; Ponikowski, P; Simmons, P; Simonson, S; Soffer, J, 2023) |
| "We examined the effects of istaroxime in patients hospitalized for acute heart failure (AHF) related Society for Cardiovascular Angiography and Interventions (SCAI) stage B pre-cardiogenic shock (CS)." | 5.51 | Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC). ( Chioncel, O; Cotter, G; Davison, B; Filippatos, G; Mebazaa, A; Metra, M; Novosadova, M; Ponikowski, P; Simmons, P; Simonson, S; Soffer, J, 2022) |
| "Istaroxime is a new luso-inotropic compound that stimulates cardiac contractility and relaxation in healthy and failing animal models and in patients with acute heart failure (AHF) syndrome." | 5.39 | Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. ( Barassi, P; Bartolommei, G; Bianchi, G; Ferrandi, M; Ferrari, P; Molinari, I; Moncelli, MR; Reina, C; Tadini-Buoninsegni, F; Tripodi, MG, 2013) |
| "Istaroxime failed to increase SERCA activity in skeletal muscle microsomes devoid of phospholamban." | 5.35 | Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model. ( Alemanni, M; Altomare, C; Barassi, P; Chisci, R; Ferrari, P; Micheletti, R; Mostacciuolo, G; Rocchetti, M; Zaza, A, 2008) |
| "Istaroxime is a sodium-potassium adenosine triphosphatase (ATPase) inhibitor with the unique property of increasing sarcoplasmic reticulum calcium ATPase (SERCA) isoform 2a (SERCA2a) activity." | 5.34 | Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. ( Barassi, P; Bianchi, G; Ferrandi, M; Ferrari, P; Giacalone, G; Micheletti, R; Moro, B; Palazzo, F; Parodi, O; Schiavone, A, 2007) |
| "Istaroxime decreases PCWP, increases SBP, and decreases diastolic stiffness in patients with acute heart failure syndrome." | 5.14 | Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in P ( Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Grzybowski, J; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Shah, SJ; Valentini, G, 2009) |
| "We examined the hemodynamic, echocardiographic, and neurohormonal effects of intravenous istaroxime in patients hospitalized with heart failure (HF)." | 5.13 | Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. ( Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Valentini, G, 2008) |
| " Albeit few, pediatric studies involving levosimendan suggest similar pharmacokinetics to adults with heart failure, an efficacy at least equal to that of milrinone, favorable myocardial oxygen effects, and an ability to decrease concomitant catecholamine dosing." | 4.87 | Newer inotropes in pediatric heart failure. ( Hoffman, TM, 2011) |
| "Sigma-Tau Ind Farm Riunite SpA and Debiopharm SA are developing istaroxime, the lead in a series of Na(+)/K(+)-ATPase inhibitors, for the potential treatment of cardiac failure." | 4.84 | Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure. ( Wehrens, XH, 2007) |
| " Considering that heart failure is a potential side effect of current PC treatments, especially in elderly patients, istaroxime might combine beneficial cardiac and anti-cancer properties." | 3.85 | Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium. ( Curcic, P; Eaton, DM; Khafaga, M; Knez, I; Kolesnik, E; Köstenberger, M; Lewinski, DV; Pichler, M; Pieske, B; Rainer, PP; Schwantzer, G; Vafiadis, A; Wallner, M, 2017) |
| " Some compounds showed inhibitory potencies of the Na(+),K(+)-ATPase higher than Istaroxime and many of the compounds tested in vivo were safer than digoxin, the classic digitalis compound currently used for the treatment of congestive heart failure as inotropic agent." | 3.76 | Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold. ( Armaroli, S; Banfi, L; Benicchio, A; Carzana, G; Cerri, A; Ferrari, P; Giacalone, G; Gobbini, M; Marazzi, G; Micheletti, R; Moro, B; Sputore, S; Torri, M; Zappavigna, MP, 2010) |
| "Istaroxime is a new luso-inotropic compound selected for the treatment of acute heart failure syndromes, which reduces sodium-potassium adenosine triphosphatase (ATPase) activity and stimulates the sarcoplasmic calcium ATPase isoform 2 reuptake function." | 3.74 | Istaroxime: a new luso-inotropic agent for heart failure. ( Borsini, F; Carminati, P; Gagnol, JP; Lo Giudice, P; Loi, FM; Mattera, GG; Vanoli, E, 2007) |
| "Istaroxime (PST2744) is a luso-inotrope that stimulates the sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a without chronotropic effects." | 2.73 | A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. ( Amato, A; Carminati, P; Cowart, D; Ghali, JK; Gheorghiade, M; Haynos, W; Rayburn, BK; Smith, WB; Torre-Amione, G; Valentini, G; Zhang, D, 2007) |
| "Istaroxime is a unique agent with both inotropic and lusitropic properties which is currently being studied for the treatment of AHFS." | 2.45 | Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? ( Blair, JE; Filippatos, GS; Gheorghiade, M; Harinstein, ME; Khan, H; Metra, M; Porchet, H; Sabbah, HN; Valentini, G; Vogel, M, 2009) |
| "Several therapies commonly used for the treatment of acute heart failure syndromes (AHFS) present some well-known limitations and have been associated with an early increase in the risk of death." | 2.44 | Overview of emerging pharmacologic agents for acute heart failure syndromes. ( Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F, 2008) |
| "Istaroxime is a new luso-inotropic compound that stimulates cardiac contractility and relaxation in healthy and failing animal models and in patients with acute heart failure (AHF) syndrome." | 1.39 | Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. ( Barassi, P; Bartolommei, G; Bianchi, G; Ferrandi, M; Ferrari, P; Molinari, I; Moncelli, MR; Reina, C; Tadini-Buoninsegni, F; Tripodi, MG, 2013) |
| " An ideal inotropic drug should restore effective tissue perfusion by enhancing myocardial contractility without causing adverse effects." | 1.36 | Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? ( Campia, U; Gheorghiade, M; Nodari, S, 2010) |
| "Istaroxime failed to increase SERCA activity in skeletal muscle microsomes devoid of phospholamban." | 1.35 | Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model. ( Alemanni, M; Altomare, C; Barassi, P; Chisci, R; Ferrari, P; Micheletti, R; Mostacciuolo, G; Rocchetti, M; Zaza, A, 2008) |
| "Istaroxime is a sodium-potassium adenosine triphosphatase (ATPase) inhibitor with the unique property of increasing sarcoplasmic reticulum calcium ATPase (SERCA) isoform 2a (SERCA2a) activity." | 1.34 | Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. ( Barassi, P; Bianchi, G; Ferrandi, M; Ferrari, P; Giacalone, G; Micheletti, R; Moro, B; Palazzo, F; Parodi, O; Schiavone, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (53.13) | 29.6817 |
| 2010's | 9 (28.13) | 24.3611 |
| 2020's | 5 (15.63) | 2.80 |
| Authors | Studies |
|---|---|
| Metra, M | 4 |
| Chioncel, O | 3 |
| Cotter, G | 3 |
| Davison, B | 2 |
| Filippatos, G | 3 |
| Mebazaa, A | 3 |
| Novosadova, M | 2 |
| Ponikowski, P | 2 |
| Simmons, P | 2 |
| Soffer, J | 2 |
| Simonson, S | 2 |
| Avvisato, R | 1 |
| Jankauskas, SS | 1 |
| Santulli, G | 1 |
| Pagnesi, M | 1 |
| Adamo, M | 1 |
| Tedford, RJ | 1 |
| Silverman, DN | 1 |
| Collins, SP | 1 |
| Butler, J | 1 |
| Wallner, M | 1 |
| Khafaga, M | 1 |
| Kolesnik, E | 1 |
| Vafiadis, A | 1 |
| Schwantzer, G | 1 |
| Eaton, DM | 1 |
| Curcic, P | 1 |
| Köstenberger, M | 1 |
| Knez, I | 1 |
| Rainer, PP | 1 |
| Pichler, M | 1 |
| Pieske, B | 2 |
| Lewinski, DV | 1 |
| Ferrandi, M | 3 |
| Barassi, P | 3 |
| Tadini-Buoninsegni, F | 1 |
| Bartolommei, G | 1 |
| Molinari, I | 1 |
| Tripodi, MG | 1 |
| Reina, C | 1 |
| Moncelli, MR | 1 |
| Bianchi, G | 3 |
| Ferrari, P | 6 |
| Huang, CL | 1 |
| Hohendanner, F | 1 |
| Ljubojević, S | 1 |
| MacQuaide, N | 1 |
| Sacherer, M | 1 |
| Sedej, S | 1 |
| Biesmans, L | 1 |
| Wakula, P | 1 |
| Platzer, D | 1 |
| Sokolow, S | 1 |
| Herchuelz, A | 1 |
| Antoons, G | 1 |
| Sipido, K | 1 |
| Heinzel, FR | 1 |
| Gheorghiade, M | 10 |
| Blair, JE | 3 |
| Filippatos, GS | 3 |
| Macarie, C | 2 |
| Ruzyllo, W | 2 |
| Korewicki, J | 2 |
| Bubenek-Turconi, SI | 2 |
| Ceracchi, M | 2 |
| Bianchetti, M | 2 |
| Carminati, P | 6 |
| Kremastinos, D | 2 |
| Valentini, G | 5 |
| Sabbah, HN | 6 |
| Dec, GW | 1 |
| Rocchetti, M | 1 |
| Alemanni, M | 1 |
| Mostacciuolo, G | 1 |
| Altomare, C | 1 |
| Chisci, R | 1 |
| Micheletti, R | 4 |
| Zaza, A | 1 |
| Khan, H | 1 |
| Vogel, M | 1 |
| Harinstein, ME | 1 |
| Porchet, H | 1 |
| Shah, SJ | 1 |
| Grzybowski, J | 1 |
| Teerlink, JR | 1 |
| Zacà, V | 1 |
| Cas, LD | 1 |
| Gobbini, M | 1 |
| Armaroli, S | 1 |
| Banfi, L | 1 |
| Benicchio, A | 1 |
| Carzana, G | 1 |
| Giacalone, G | 2 |
| Marazzi, G | 1 |
| Moro, B | 2 |
| Sputore, S | 1 |
| Torri, M | 1 |
| Zappavigna, MP | 1 |
| Cerri, A | 1 |
| Meyer, P | 1 |
| White, M | 1 |
| Keller, RF | 1 |
| Lerch, R | 1 |
| Hullin, R | 1 |
| Campia, U | 1 |
| Nodari, S | 1 |
| Hoffman, TM | 1 |
| Ambrosy, AP | 1 |
| Adamson, PB | 1 |
| Vanoli, E | 2 |
| Mattera, GG | 2 |
| Germany, R | 1 |
| Gagnol, JP | 2 |
| Schwartz, PJ | 1 |
| deGoma, EM | 1 |
| Vagelos, RH | 1 |
| Fowler, MB | 1 |
| Ashley, EA | 1 |
| Palazzo, F | 1 |
| Schiavone, A | 1 |
| Parodi, O | 1 |
| Lo Giudice, P | 1 |
| Loi, FM | 1 |
| Borsini, F | 1 |
| Imai, M | 1 |
| Cowart, D | 2 |
| Amato, A | 2 |
| Ghali, JK | 1 |
| Smith, WB | 1 |
| Torre-Amione, G | 1 |
| Haynos, W | 1 |
| Rayburn, BK | 1 |
| Zhang, D | 1 |
| Wehrens, XH | 1 |
| Skóra, E | 1 |
| Bilińska, ZT | 1 |
| De Luca, L | 1 |
| Parissis, JT | 1 |
| Böhm, M | 1 |
| Voors, AA | 1 |
| Nieminen, M | 1 |
| Zannad, F | 1 |
| Rhodes, A | 1 |
| El-Banayosy, A | 1 |
| Dickstein, K | 1 |
| Felt, V | 1 |
| Stárka, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Assess the Hemodynamic Effects of Istaroxime, a Novel Lusinotropic Agent, in Patients Hospitalized With Worsening Heart Failure and a Reduced Left Ventricular Systolic Function[NCT00616161] | Phase 2 | 120 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Escalating Dose Phase I Interaction Study to Evaluate the Pharmacokinetics, Tolerability and Pharmacodynamics of Three Dose Levels of Debio 0614 (Istaroxime) as a 24-hour Constant Rate IV Infusion in Combinat[NCT00869115] | Phase 1 | 0 participants (Actual) | Interventional | 2009-06-30 | Withdrawn (stopped due to The study was not started due to a re-evaluation of the istaroxime development program) | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Staggered Dose-escalating Phase IIb Study of the Safety and Efficacy of Istaroxime Over 24 Hours at Three Doses in Acute Decompensated Heart Failure Patients (The IGNITE Trial)[NCT00838253] | Phase 2 | 0 participants (Actual) | Interventional | 2009-06-30 | Withdrawn (stopped due to The study was not started due to a re-evaluation of the istaroxime development program) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for etiocholanolone and Heart Failure
| Article | Year |
|---|---|
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Topics: Acute Disease; Animals; Cardiotonic Agents; Dobutamine; Etiocholanolone; Heart Failure; Hemodynamics | 2009 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failur | 2009 |
[What is new in the medical management of acute heart failure?].
Topics: Acute Disease; Adenosine; Algorithms; Cardiotonic Agents; Diuretics; Drug Therapy, Combination; Etio | 2010 |
Newer inotropes in pediatric heart failure.
Topics: Cardiotonic Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Etiocholanolone; | 2011 |
Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
Topics: Animals; Cardiac Output, Low; Etiocholanolone; Heart Failure; Humans; Models, Biological; Sarcoplasm | 2011 |
Emerging therapies for the management of decompensated heart failure: from bench to bedside.
Topics: Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Cardiac Myosins; Cardiotonic A | 2006 |
Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Topics: Acute Disease; Animals; Cardiotonic Agents; Enzyme Inhibitors; Etiocholanolone; Heart Failure; Human | 2007 |
[New therapeutic goals--new drugs in heart failure treatment].
Topics: Amides; Cardiovascular Agents; Etiocholanolone; Fumarates; Heart Failure; Humans; Neovascularization | 2007 |
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans | 2008 |
5 trials available for etiocholanolone and Heart Failure
18 other studies available for etiocholanolone and Heart Failure
| Article | Year |
|---|---|
Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart Failure.
Topics: Cardiotonic Agents; Etiocholanolone; Heart Failure; Humans; Sarcoplasmic Reticulum Calcium-Transport | 2023 |
Istaroxime in HFpEF: Can We Relax Already?
Topics: Cardiotonic Agents; Etiocholanolone; Heart Failure; Humans; Stroke Volume | 2023 |
Istaroxime in acute heart failure: the holy grail is at HORIZON?
Topics: Cardiotonic Agents; Etiocholanolone; Heart Failure; Humans | 2020 |
Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.
Topics: Antineoplastic Agents; Cardiotonic Agents; Dose-Response Relationship, Drug; Etiocholanolone; Heart; | 2017 |
Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
Topics: Animals; Calcium; Calcium-Binding Proteins; Dogs; Etiocholanolone; Guinea Pigs; Heart Failure; Human | 2013 |
SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications.
Topics: Animals; Calcium; Calcium-Binding Proteins; Etiocholanolone; Heart Failure; Humans; Male; Sarcoplasm | 2013 |
Intracellular dyssynchrony of diastolic cytosolic [Ca²⁺] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure.
Topics: Aniline Compounds; Animals; Calcium Signaling; Calcium-Transporting ATPases; Colforsin; Cytosol; Dia | 2013 |
Istaroxime in heart failure new hope or more hype.
Topics: Acute Disease; Cardiotonic Agents; Etiocholanolone; Heart Failure; Heart Rate; Humans; Stroke Volume | 2008 |
Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model.
Topics: Animals; Disease Models, Animal; Etiocholanolone; Guinea Pigs; Heart Failure; Myocytes, Cardiac; Sar | 2008 |
Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold.
Topics: Androstanes; Animals; Enzyme Inhibitors; Etiocholanolone; Guinea Pigs; Heart Failure; Sodium-Potassi | 2010 |
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobut | 2010 |
Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure.
Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Etiocholanolone; Heart Failure; Hemodynamics; Ventric | 2003 |
Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure.
Topics: Cardiotonic Agents; Etiocholanolone; Heart Failure; Humans; Models, Cardiovascular; Myocardial Contr | 2007 |
Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes.
Topics: Aged; Cardiotonic Agents; Etiocholanolone; Female; Heart Failure; Humans; Male | 2007 |
Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Topics: Animals; Cardiotonic Agents; Enzyme Activation; Etiocholanolone; Guinea Pigs; Heart Failure; Humans; | 2007 |
Istaroxime: a new luso-inotropic agent for heart failure.
Topics: Animals; Blood Pressure; Cricetinae; Dogs; Etiocholanolone; Heart Failure; Heart Rate; Male; Sodium- | 2007 |
Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Dogs; Echocardiography, Doppler; Electrocardiography; E | 2007 |
[Excretion of steroid metabolites by women with cardiac thyrotoxicosis].
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aldosterone; Androsterone; Et | 1964 |